PROGRAM CHAIR & FACULTY SPEAKER
David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Cancer Center
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Boston, MA
PROGRAM OVERVIEW
This enduring TeleECHO podcast will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas (NMSCs). Over the course of this activity there will be discussion of the data from clinical trials assessing the clinical profiles of new systemic therapies with different mechanisms of action for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation; integrating methods for identifying and managing side effects associated with new systemic therapies for the treatment of patients with advanced NMSCs into routine clinical practice; categorizing the types of patients with unresectable NMSCs who may benefit from new systemic therapies for the treatment of advanced NMSCs; and lastly enhancing patient management including care coordination through participation in interdisciplinary care teams for those with advanced NMSCs failing or not amenable to surgery or radiation.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based dermatologists, oncologists, and dermato-oncologists who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.
EDUCATIONAL OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate data from clinical trials assessing the clinical profiles of new systemic therapies with different mechanisms of action for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation
- Integrate methods for identifying and managing side effects associated with new systemic therapies for the treatment of patients with advanced NMSCs into routine clinical practice
- Categorize the types of patients with unresectable NMSCs who may benefit from new systemic therapies for the treatment of advanced NMSCs
- Enhance patient management including care coordination through participation in interdisciplinary care teams for those with advanced NMSCs failing or not amenable to surgery or radiation
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.33 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Miller has received honoraria for participation on advisory boards for Merck, EMD Serono, Regeneron, Sanofi Genzyme, Pfizer, Castle Biosciences and Checkpoint Therapeutics. He has stock in Checkpoint Therapeutics and has received research funding from Regeneron, Kartos Therapeutics, NeoImmuneTech, Project Data Sphere, ECOG-ACRIN and the American Skin Association.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, MD, Medical Director for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME information and faculty disclosures
- Participate in the enduring activity
- Complete the online post-test and evaluation
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
GUESTS
Dan, Patient
Arlington, VA
Nancy, Spouse
Arlington, VA
PROGRAM OVERVIEW
In this enduring podcast, we will hear the perspectives of the patient and caregiver regarding non-melanoma skin cancer and the journey to diagnosis and treatment; this will include perspectives on effective communication, team-based clinical care, and their experience participating in a clinical trial.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based dermatologists, oncologists, and dermato-oncologists who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.
EDUCATIONAL OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Integrate methods for identifying and managing side effects associated with new systemic therapies for the treatment of patients with advanced NMSCs into routine clinical practice
- Enhance patient management including care coordination through participation in interdisciplinary care teams for those with advanced NMSCs failing or not amenable to surgery or radiation
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.33 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Dan, patient | Reports no relevant relationships with a commercial entity or manufacturer. |
| Nancy, spouse | Reports no relevant relationships with a commercial entity or manufacturer. |
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, MD, Medical Director for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME information and faculty disclosures
- Participate in the enduring activity
- Complete the online post-test and evaluation
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: November 3, 2022
EXPIRATION DATE: November 3, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
